SCOTTSDALE, AZ–(Marketwired – June 01, 2017) – Lattice Biologics Ltd. (TSX VENTURE: LBL) (OTCQB: LBLTF) (“Lattice Biologics” or the “Company“) is pleased to announce that it has been approved for re-accreditation by the American Association of Tissue Banks (“AATB“) for processing, storage, and distribution of musculoskeletal tissue and skin through September 2019.
The multi-year accreditation was received following a process including on-site inspections and audits of the Company’s tissue processing facility in Scottsdale, Arizona. The approval establishes that Lattice Biologics meets or exceeds the AATB’s Standards for Tissue Banking, which are recognized in the United States and around the world as the definitive guide for tissue banking.
“This voluntary accreditation demonstrates Lattice Biologics’ longstanding commitment to a strong quality control environment and respect for the highest standards for patients and the medical community,” said Guy Cook, CEO of Lattice Biologics. “We are excited to secure this key approval which will advance the Company and its sales objectives.”
Lattice continues to develop products in the following five areas: 1) musculoskeletal products used primarily in spine indications; 2) Accelular Dermal Matrix used in breast reconstruction and sports medicine; 3) demineralized bone matrix putty; 4) precision diagnostics tools for cancer screening; and 5) amnion based products. The Company has successfully increased production levels to meet surgeon demand and is having great success with the launch of its two newest products, the Accellular Dermal Matrix scaffold (AdMatrix) and the amnion based products, AmnioBoost and AmnioBlast.
About the American Association of Tissue Banks:
The AATB is a professional, non-profit, scientific and educational organization that has been accrediting tissue banks since 1986. It is the only national tissue banking organization in the United States, and its membership totals more than 130 accredited tissue banks and 2,000 individual members. These institutions distribute in excess of two million allografts for more than 1.75 million tissue transplants performed annually in the United States. AATB improves and saves lives by promoting the safety, quality and availability of donated human tissue by publishing standards, accrediting tissue banks, and certifying personnel.
Lattice Biologics Ltd.
Guy Cook,
Chief Executive Officer
Telephone No: (480) 563-0800
About Lattice Biologics Ltd.:
Lattice Biologics Ltd. is an emerging precision medicine leader in the field of cellular therapies and tissue engineering, with an emphasis on bone, skin, and cartilage regeneration. As a manufacturer of the highest quality allografts, Lattice is focused on next generation products to improve surgical outcomes.
Versatile allografts for a variety of surgical applications:
- Enhancing fusion in spine surgery
- Enhancing breast reconstruction post mastectomy for breast cancer patients
- Sports medicine indications, including ACL repair
- Promotion of bone regeneration in foot and ankle surgery
- Promotion of cranial healing following neurosurgery
- Enhancing wound repair in burn victims
- Subchondral bone defect repair in knee and other joint surgeries
The Company is currently exploring new technologies in regenerative and personalized medicine:
- All natural amniotic fluid supplement for arthritic joints
- Personalized Cancer Diagnostics – revolutionary high-throughput precision chemotherapy screening
Lattice Biologics operates headquarters, laboratory and manufacturing facilities in Scottsdale, Arizona as well as offices in Toronto Ontario. The Company maintains all necessary licensures to process and sell its tissue engineered products within the U.S. and internationally. This includes Certificates to Foreign Governments from the U.S. Food and Drug Administration (FDA) and registrations for 29 countries, which allow the export of bone, tendon, meniscus, ligament, soft tissue, and cartilage products outside of the U.S.
Lattice Biologics (TSX-V: LBL) (OTCQB: LBLTF) became a publicly traded company on January 4, 2016.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Statement on Forward-Looking Information:
Certain information contained in this news release constitutes “forward-looking statements” within the meaning of the ‘safe harbour’ provisions of the United States Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements herein, other than statements of historical fact, are to be considered forward looking. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “potential”, “future”, “expected”, “could”, “possible”, “goal”, “intends”, “will” or similar expressions. Forward-looking statements in this news release include, without limitation: information pertaining to the Company’s strategy, plans, or future financial performance, such as statements with respect to future revenues or products, and other statements that express management’s expectations or estimates of future performance. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Lattice to be materially different from those expressed or implied by such forward-looking statements.
Forward-looking statements are necessarily based upon a number of factors and assumptions that, while considered reasonable by management as of the date such statements are made, are inherently subject to significant business, economic and competitive uncertainties and contingencies. The factors and assumptions that could prove to be incorrect, include, but are not limited to: that market prices will be consistent with expectations, the continued availability of capital and financing, and that general economic, market and business conditions will be consistent with expectations. The forward-looking statements are not guarantees of future performance. We disclaim any obligation to update or revise any forward-looking statements, except as required by law. Readers are cautioned not to put undue reliance on these forward-looking statements.
Subscribe to Lattice News Updates
Follow us on Twitter: @LatticeBio
Media Contact:
[email protected]
Lattice Biologics Ltd.
(TSX-V: LBL) (OTCQB: LBLTF)
16701 N 90th Street, Suite#101
Scottsdale, AZ 85260
480-563-0800 Office
[email protected]
www.LatticeBiologics.com
